Effects of a nine-strain bacterial synbiotic compared to simethicone in colicky babies – an open-label randomised study
Author(s) -
Jacek Piątek,
Małgorzata Bernatek,
Hanna Krauss,
M Wojciechowska,
Zuzanna Chęcińska-Maciejewska,
Przemysław Kaczmarek,
Henning Sommermeyer
Publication year - 2021
Publication title -
beneficial microbes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.114
H-Index - 40
eISSN - 1876-2891
pISSN - 1876-2883
DOI - 10.3920/bm2020.0160
Subject(s) - evening , crying , medicine , bifidobacterium bifidum , lactobacillus paracasei , lactobacillus casei , bifidobacterium longum , lactobacillus rhamnosus , bifidobacterium breve , lactobacillus salivarius , lactobacillus acidophilus , probiotic , gastroenterology , bifidobacterium , zoology , lactobacillus , biology , food science , bacteria , genetics , physics , astronomy , psychiatry , fermentation
The aim of the study was to determine effects of administration of simethicone and a multi-strain synbiotic on the crying behaviour of colicky babies. The study design consisted of an open-label, two parallel treatment group study involving 87 infants aged 3-6 weeks with infantile colic (defined as crying episodes lasting 3 or more hours per day and occurring at least 3 days per week within 3 weeks prior to enrolment) randomly, unequally [1:1.5] assigned to receive simethicone (n=33) or a multi-strain synbiotic (n=54) orally for 4 weeks. The multi-strain synbiotic contained Lactobacillus acidophilus LA-14, Lacticaseibacillus casei R0215, Lacticaseibacillus paracasei Lp-115, Lacticaseibacillus rhamnosus GG, Ligilactobacillus salivarius Ls-33, Bifidobacterium lactis Bl-04, Bifidobacterium bifidum R0071, Bifidobacterium longum R0175 and fructooligosaccharides). Primary outcome measures were the responder rates (effect ≥50% reduction from baseline) of the measures ‘crying days last 3 weeks’, ‘average evening crying duration last 3 weeks’ and ‘reduction of average number of crying phases per day last three weeks’ at the end of treatment. The study is registered at ClinicalTrials.gov under NCT 04487834. Significantly higher responder rates (effect ≥50% reduction from baseline) of the multi-strain synbiotic compared to simethicone were found for the measures ‘crying days last 3 weeks’ (72% vs 18%, P<0.0001) and ‘average evening crying duration last 3 weeks’ (85% vs 39%, P=0.0001). No significant difference was found for the measure ‘reduction of average number of crying phases per day last three weeks’ (50% vs 42%, P=0.4852). No adverse effects were reported for the two treatment groups. Based on these results, the multi-strain synbiotic can be considered as an interesting therapeutic possibility for the treatment of infantile colic, worthwhile to be investigated further in non-clinical and clinical studies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom